Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZP5-9676 for the Treatment of Soil-Transmitted Helminthiasis
NCT06128447Phase 3Recruiting
- Sponsor
- Zero Point Five Therapeutics
- Start
- Feb 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ZP5-9676 in soil-transmitted helminthiasis (STH), sponsored by Zero Point Five Therapeutics. Started Feb 2025; status: recruiting.
02
Drugs
ZP5-9676
03
Conditions
soil-transmitted helminthiasis (STH)
Beyond the preview
Go deeper on NCT06128447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06128447.